The growth of activated human T lymphocytes in response to interleukin-2 (IL-2) is suppressed by transforming growth factor-beta (TGF-beta). This study presents data that show a diminished response of two human lymphoma cell lines to physiologic regulation by TGF-beta. Cell line L-428 was derived from the malignant pleural effusion of a patient with far advanced nodular sclerosing Hodgkin's disease and has been shown to have clonal gene rearrangements characteristic of both B and T lymphocytes. Cell line Mac-1 was derived from the blood of a patient with clinically indolent cutaneous T-cell lymphoma. Both cell lines express the Hodgkin's disease associated antigen, Ki-1. These Ki-1 positive lymphomas are shown to secrete TGF-beta into serum-free culture media. The addition of picogram quantities of exogenous TGF-beta to cell cultures of indolent Ki-1 lymphoma (Mac-1) suppresses IL-2-dependent mitosis; however, the suppression is less than 45%. This suppression correlates with a decrease in the number of IL-2 receptors. No inhibition of Ki-1 positive Hodgkin's cells (L-428) was observed, and proliferation dependent on polyclonal IL-2 was either not affected or was slightly potentiated by TGF-beta. Receptor analysis indicates the absence of IL-2 and TGF-beta receptors on L-428 cells. Thus, these Ki-1 lymphomas derived from activated lymphocytes appear to secrete TGF-beta activity but continue to proliferate because of defective suppression of IL-2 (and related lymphokine)-dependent DNA synthesis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1880714PMC

Publication Analysis

Top Keywords

ki-1 positive
16
transforming growth
8
growth factor-beta
8
positive lymphoma
8
lymphoma cell
8
cell lines
8
tgf-beta cell
8
hodgkin's disease
8
secrete tgf-beta
8
ki-1
7

Similar Publications

Intravascular accumulation of atypical large lymphoid cells is a rare condition that necessitates a differential diagnosis of intravascular lymphoma (IVL). Recently, a non-neoplastic condition known as benign atypical intravascular CD30+ T-cell proliferation (BAITP) has been identified. This condition is characterized by CD30+ and CD3+ or CD4+ atypical T-cells and is often associated with trauma and chronic inflammation.

View Article and Find Full Text PDF

Purpose: Patients with relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL) generally have poor prognoses and limited treatment options. This study evaluated the efficacy of a novel CD30/CD16A bispecific innate cell engager, acimtamig (AFM13), in patients with R/R PTCL.

Patients And Methods: Patients included those with CD30 expression in ≥1% of tumor cells and who were R/R following ≥1 prior line of systemic therapy.

View Article and Find Full Text PDF

Genomic analysis reveals molecular characterization of CD30 and CD30 extranodal natural killer/T-cell lymphomas (ENKTLs).

Hum Pathol

October 2024

Department of Pathology, School of Basic Medical Sciences and Qilu Hospital, Shandong University, Jinan, China. Electronic address:

Article Synopsis
  • Extranodal natural killer/T-cell lymphoma (ENKTL) is common in Asians, but its molecular characteristics are not well understood; this study focuses on CD30 expression and genetics of samples.
  • CD30 was found to be positive in approximately 55.74% of ENKTLs, and significant mutations were noted in various genes related to cell function and cancer progression, highlighting the involved pathways.
  • The study discovered higher BCL10 expression in ENKTL compared to normal tissues, suggesting that BCL10 inhibitors may offer a new treatment option for this type of lymphoma.
View Article and Find Full Text PDF

Standardization of CD30 immunohistochemistry staining among three automated immunostaining platforms.

Pathol Int

September 2024

Department of Pathology and Laboratory Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan.

Article Synopsis
  • Identifying CD30 expression through immunohistochemistry is crucial for treating lymphomas with CD30-targeting antibody-drug conjugates, but no standardized staining protocol existed prior to this study.
  • The research compared three automated immunostaining platforms (Bond III, Dako Omnis, Ventana BenchMark ULTRA) using varying dilutions of a primary antibody to determine effective staining conditions.
  • The study found that adjusting antibody dilutions and cutoff values can achieve consistent CD30 staining across different platforms, with high concordance rates for diagnosing peripheral T-cell lymphomas.
View Article and Find Full Text PDF

Etoposide addition and brentuximab vedotin consolidation in first-line treatment of CD30-positive peripheral T-cell lymphoma: can we improve BV-CHP?

Lancet Haematol

September 2024

Hematology Department, Lyon Sud Hospital, Hospices Civils de Lyon, 69495 Piere Bénite, France; Lymphoma Immuno-Biology Research Unit, Inserm U1111, CIRI, Lyon, France. Electronic address:

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!